The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
 
Krishnansu Sujata Tewari
Honoraria - AstraZeneca; Clovis Oncology; Eisai; Genmab; Merck; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Genmab; Merck; Roche/Genentech; Tesaro
Research Funding - Abbvie (Inst); Genentech/Roche (Inst); Merck (Inst); Morphotek (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Coraline Dubot
No Relationships to Disclose
 
M. Valeria Caceres
No Relationships to Disclose
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Sanofi; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Genmab; Kaken Pharmaceutical; MSD K.K; Roche; Sanofi; Takeda
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical
 
Ronnie Shapira-Frommer
Honoraria - AstraZeneca; BMS; Mediso; MSD Oncology; NeoPharm; Novartis; Roche
Consulting or Advisory Role - MSD Oncology
Research Funding - MSD (Inst)
 
Pamela Salman
Consulting or Advisory Role - Lilly; Merck Serono; Novartis; Roche/Genentech
Speakers' Bureau - Lilly; Novartis; Roche/Genentech
 
Eduardo Yañez
Honoraria - Abbott Laboratories
Consulting or Advisory Role - Abbott Laboratories; Bristol-Myers Squibb; Merck Serono
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Expert Testimony - Abbott Laboratories
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Mahmut Gumus
Honoraria - GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Consulting or Advisory Role - Amgen (Inst); Gen (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Roche; Takeda (Inst)
Speakers' Bureau - Amgen (Inst); MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst)
Research Funding - Amgen (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Mivael Olivera Hurtado de Mendoza
No Relationships to Disclose
 
Vanessa Samouëlian
Consulting or Advisory Role - GlaxoSmithKline; Merck
 
Vincent Castonguay
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMS Brazil; Eisai; GlaxoSmithKline Canada; Ipsen; Janssen; Merck; Pfizer
Research Funding - AstraZeneca Canada (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Merck (Inst); Pfizer (Inst)
 
Alexander Arkhipov
No Relationships to Disclose
 
Cumhur Tekin
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kan Li
Employment - Merck
 
Stephen Michael Keefe
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genmab; GlaxoSmithKline; ImmunoGen; MSD; PharmaMar; Seagen
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup